Related by context. Frequent words. (Click for all words.) 75 ® bortezomib 72 refractory chronic lymphocytic 72 DNA methyltransferase inhibitors 70 targeted immunotherapies 70 R sorafenib tablets 70 Initiates Phase II 70 oncolytic virus therapies 69 Annamycin 69 Completes Patient Enrollment 69 Panzem R NCD 68 drug Treanda 68 metastatic colorectal 68 gets USFDA nod 68 VEGFR2 inhibitor 68 ThermoDox R 68 Ixempra 68 Receives Orphan Drug Designation 68 lung pancreatic 68 AVEO Pharmaceuticals NASDAQ 68 Genentech Wyeth Pharmaceuticals 68 MKC# MT 68 metastatic HER2 negative 68 hepatitis C lupus 67 Archexin 67 inflammation autoimmune diseases 67 systemic anaplastic large 67 LungAlert TM 67 R bortezomib 67 combines Zetia 67 psoriasis rheumatoid arthritis 67 Other ImmunoGen collaborative 67 GVAX R 67 ZFP Therapeutics 67 non personalized allogeneic 67 sorafenib tablets 66 anthracycline taxane 66 deCODE AF TM 66 Tibotec Therapeutics division 66 advanced carcinoid 66 PNP inhibitor 66 YOUR LOCAL ANIMAL SHELTER 66 Panzem R 66 Through Glycoscience R 66 orderonlineviagra 66 Meets Primary Endpoint 66 Vidaza R 66 Temsirolimus 66 cystic fibrosis inflammation autoimmune 66 hormone refractory metastatic prostate 66 multi kinase inhibitor 66 FUSILEV ® 65 phenylketonuria PKU developed 65 autoimmune disorders asthma 65 var arrMeta = 65 dermatology therapies 65 R sipuleucel T 65 deforolimus 65 oral isoform selective HDAC 65 Palifosfamide delivers 65 community AABB SmartBrief 65 2 methoxyestradiol 65 thetreatment 65 Emergent marketed 65 interferon gamma 1b 65 comprise Alnylam RNAi 65 Vytorin combines 65 leading lipid nanoparticle 65 var arrUrl = 64 apoptosis proteins 64 catheter occlusion 64 alvespimycin 64 metastatic hormone refractory 64 BY DANNY GALLAGHER 64 urinary bladder wall 64 Staff Writer larry@gaffneyledger.com 64 Small interfering RNAs 64 Paraplatin 64 commercializes biotherapeutics 64 Crucell NV NYSE Euronext 64 By MILENKO MARTINOVICH 64 Presents Preclinical Data 64 novel oral tubulin 64 Amgen discovers develops 64 autologous cellular immunotherapy 64 rheumatoid arthritis inflammatory bowel 64 overactive bladder AA# 64 candidate ridaforolimus 64 fluoroquinolone class 64 immunotherapeutic agent 64 Amgen discovers develops manufactures 64 By RICK KRETZSCHMAR 64 TRAIL receptor antibodies 64 * Azixa 64 Inc. Nasdaq OXGN 64 addressing idiopathic pulmonary 64 liposomal formulation 64 colorectal lung 64 MKC# 64 Auxilium transmucosal film 64 Romidepsin 64 FDA Accepts